Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures
August 30 2022 - 04:05PM
Business Wire
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical
company advancing innovative precision therapeutics targeting
debilitating and rare diseases, today presented preclinical data at
the 14th International Conference on Osteogenesis Imperfecta (OI
2022) demonstrating the potential of its novel targeted therapeutic
NOV004 to treat fracture in osteogenesis imperfecta (OI) by
promoting accelerated increases in bone density, strength, and
healing directly at the site of bone fracture. NOV004 is expected
to enter Phase 1 clinical studies in 2023 and advance to a lead
indication in osteogenesis imperfecta.
Karen Smith, M.D., Ph.D., chief medical officer of Quince
Therapeutics, said, “In preclinical studies of severe OI Type 3 in
vivo models, we have been able to demonstrate a two-fold
improvement in the ratio of calcified bone and a three-fold
improvement in maximum load over vehicle. In addition, there also
was a statistically significant difference in the force required to
refracture compared to free drug and vehicle in a normal healthy
mouse model of fracture healing. Importantly, we accomplished this
significantly accelerated bone repair with no ectopic bone
formation observed.”
OI 2022 Presentation Highlights
NOV004 is a systemically administered bone anabolic peptide
engineered to target and concentrate at bone fracture sites. By
improving fracture site accumulation and retention, NOV004
stimulates a robust healing response in preclinical studies of
healthy normal, diabetic, osteoporotic, and OI in vivo models.
During its OI 2022 presentation titled “Fracture-targeted Anabolics
for Treatment of Osteogenesis Imperfecta Fractures,” the company
highlighted several preclinical results demonstrating the efficacy
of NOV004 in fractures induced in the OI in vivo experiments,
including:
- High affinity to bone fractures: NOV004 was prepared by
synthesizing an abaloparatide-like peptide conjugated to a
hydroxyapatite-homing acidic oligopeptide to create a high affinity
to bone fractures. While systemically administered in a distal spot
from the fracture, NOV004 accumulates locally at the fracture site
to improve the specificity of anabolics to fractures.
- Increased retention at the fractured site: NOV004
demonstrated a marked increase in retention at the fracture site
with a 10-fold increase in AUC compared with non-targeted drug at
the fracture site.
- Increased Bone Strength: Mechanical testing yielded a
significant increase in force to fracture in the NOV004 over the
vehicle control groups.
To access Quince’s OI 2022 presentation and abstract, please
visit the Science section of the company’s corporate website.
About Quince Therapeutics
Quince Therapeutics is focused on advancing innovative precision
therapeutics targeting debilitating and rare diseases. The company
discovered a broad bone-targeting drug platform designed to
precisely deliver small molecules, peptides, or large molecules
directly to the site of bone fracture and disease to promote more
rapid healing with fewer off-target safety concerns compared to
non-targeted therapeutics. Quince’s discovery pipeline is
positioned for rapid expansion across multiple skeletal therapeutic
indications to address underserved therapeutic areas with major,
unmet medical needs, including osteogenesis imperfecta, fractures,
spinal fusion, and other severe bone diseases. The company’s lead
compound NOV004 is an anabolic peptide engineered to precisely
target and concentrate at the bone fracture site, which preclinical
studies demonstrate result in rapid increases in bone density,
strength, and healing directly at the site of bone fracture. NOV004
is expected to enter Phase 1 clinical studies in 2023 and advance
to a lead indication in osteogenesis imperfecta. For more
information, visit www.quincetx.com and follow Quince Therapeutics
on LinkedIn and @Quince_Tx on Twitter.
Forward-looking Statements
Statements in this news release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this news
release may be identified by the use of words such as “anticipate,”
“expect,” “will,” “can,” “may,” “should,” “estimate,” “project,”
“potential,” “encouraged,” “positioned,” or other similar words.
Examples of forward-looking statements include, among others,
clinical development and strategic development path for NOV004; the
company’s plans to pursue the strategic expansion of its
development pipeline; the timing and success of the company’s
clinical trials and related data, including plans and the ability
to initiate, conduct and/or complete the Phase 1 clinical studies
for NOV004 and advance to a lead indication; and the timing of
announcements and updates relating to its clinical trials and
related data; the potential therapeutic benefits, safety, and
efficacy of the company’s product candidate and discovery pipeline.
Forward-looking statements are based on Quince Therapeutics’
current expectations and are subject to inherent uncertainties,
risks, and assumptions that are difficult to predict and could
cause actual results to differ materially from what the company
expects. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Factors that could cause actual results to differ include, but are
not limited to, the risks and uncertainties described in the
section titled “Risk Factors” in the company’s Annual Report on
Form 10-K filed with the Securities and Exchange Commission (SEC)
on March 1, 2022, its Quarterly Report on Form 10-Q filed with the
SEC on August 9, 2022, and other reports as filed with the SEC.
Forward-looking statements contained in this news release are made
as of this date, and Quince Therapeutics undertakes no duty to
update such information except as required under applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220830005346/en/
Stacy Roughan Quince Therapeutics, Inc. Vice President,
Corporate Communications & Investor Relations
ir@quincetx.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2023 to Mar 2024